Medigen Vaccine Biologics Corporation reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was TWD 313.51 million compared to TWD 307.8 million a year ago. Basic loss per share from continuing operations was TWD 0.96 compared to TWD 0.96 a year ago.
For the six months, net loss was TWD 525.67 million compared to TWD 448.17 million a year ago. Basic loss per share from continuing operations was TWD 1.6 compared to TWD 1.4 a year ago.